Beijing Union Pharmaceutical Factory LTD (BUPF) is a wholly-owned enterprise of the Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences (CAMS). Originating from the Experimental Pharmaceutical Factory established in 1958 and registered in 1981, and it was renamed Beijing Union Pharmaceutical Factory in 1992. BUPF was included in the implementation scope of the central state-owned capital operation budget in 2012 and restructured in accordance with the deployment of the National Health Commission in early 2022. The company was recognized as the high-tech enterprise, and won the title of Beijing Intellectual Property Advantage Unit, and other honors.

Adhering to the tenet of “Survive by quality, develop by innovation, and contribute to human health”, BUPF has successfully developed a series of original drugs and first generic drugs for the treatment of major diseases, relying on the production-education-research integration of IMM. The company’s exclusive Class 1 drug, Bicyclol Tablets, won the First Prize of Beijing Science and Technology Award and the Second Prize of National Science and Technology Progress Award, was selected as one of the top ten scientific and technological achievements of the 60th anniversary of the founding of the CAMS, was listed on the “China Pharmaceutical Brand List” of Menet for seven times, and was recommended in 60 guidelines and clinical pathways for the hepatitis treatment and liver function protection. Since 2004, Bicyclol has been marketed in Russia, Ukraine, and other countries along the “Belt and Road”. The company participated in the development and firstly obtained the contracted production of Azvudine Tablets, and organized foreign clinical trials, supporting the conditional approval by National Medical Products Administration (NMPA) for the treatment of COVID-19, and was approved by the Ministry of Health of the Russian Federation as the marketing authorization holder.

BUPF actively implements the strategy of coordinated development for the Beijing-Hebei region. The Beijing Site is in Daxing Biomedical Industry base of Zhongguancun Science and Technology Park, with a total construction area of 46,000 square meters and is assessed as the green factory by the Ministry of Industry and Information Technology, with various production lines of tablets, dropping pills, hard capsules, creams, ointments, freeze-dried powder injection (antitumor drugs) and small volume injections. Bicyclol Tablets has obtained the GMP certification of State Service of Ukraine on Medicines and Drugs Control (SMDC), a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the GMP certification of Ministry of the Industry and Trade of the Russian Federation (MoIT). The company’s Quality Control Center has obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS). The Cangzhou branch is located at the Biomedical Industrial Park of Bohai New Zone in Hebei Province and was officially put into production in 2019 to guarantee the supply of core APIs.

Join hands and work together. BUPF will adhere to the main principle of pursuing innovation, stability and high-quality development, strive to build a new drug production-education-research base with Chinese characteristics and demonstration effects for IMM, and contribute to building a “Healthy China”.